Dr. Todd McAllister, Ph.D. - Chairman
Dr. McAllister received his Ph.D. in BioMedical Engineering from the University of California, San Diego. He is the co-founder and CEO of Cytograft Tissue Engineering, Inc. Dr. McAllister has been an early proponent of biological approaches to tissue engineering that do not require synthetic scaffolds. Dr. McAllister has also pioneered a novel business strategy within Regenerative Medicine, taking Cytograft’s lead product, the Lifeline™ Vascular Graft from inception to commercial licensure in Europe on less than $10M in private equity.
Dr. McAllister’s is also the Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta, where he oversees a broader range of cell-based
cardiovascular repair technologies. He also serves on several advisory boards, including Lumen, Biocardia, and the Medical University of South Carolina.
Dr. Nicolas L'Heureux, Ph.D.
Dr. L’Heureux received his Ph.D. in Cell Biology from Laval University in Quebec, Canada and was a post-doctoral AHA fellow in the
Department of Bioengineering at the University of California, San Diego. He is the co-founder and CSO of Cytograft Tissue Engineering, Inc. Dr. L'Heureux invented Tissue Engineering by Self-Assembly (TESA), a novel tissue engineering strategy. He advocates a biological approach to Regenerative Medicine, minimizing the inclusion of synthetic scaffolds and exogenous biomaterials.
Dr. L'Heureux is also the Co-Director of the Center for Regenerative Medicine at the St. Joseph’s Translational Research Institute in Atlanta. As a co-director he oversees research of cell-based
cardiovascular repair technologies.
Dr. Robert J. Robbins, MD.
Dr. Robert C. Robbins is both a professor and the Chairman of the Department of Cardiothoracic Surgery at Stanford University School of Medicine. He also serves as director of the Stanford Cardiovascular Institute, the Cardiothoracic Transplantation Laboratory, and the Heart, Heart/Lung and Lung transplant programs. He attended the University of Mississippi Medical Center where he received his MD and completed his general surgical training. He completed his Cardiothoracic Surgery Residency at Stanford University.
In addition to his work at Stanford, Dr. Robbins is also a manuscript reviewer for a number of prestigious journals including the New England Journal of Medicine, Annals of Thoracic Surgery, and the Journal of Thoracic and Cardiovascular Surgery. He also serves on the editorial board of the Journal of Thoracic and Cardiovascular Surgery, Cardiac Surgery Digest, the Journal of Heart and Lung Transplantation, and Innovations.
Jose M. Malbran
Jose Malbran has extensive experience in the private banking industry with significant regional exposure throughout Latin America, Europe, the Middle East and Africa. He has spent more than 30 years at Merrill Lynch in successive Private Client senior management roles including the Chairman of the the International Private Client Group.
Over the last 20 years, Mr. Malbran's leadership has fostered productivity and profitability. He has served as District Director for Southern Latin America, giving him the responsibility of overseeing
the International Private Client business in Panama, Caracas, Sao Paulo, Montevideo, Santiago (Chile), as well as ML Banque Suisse in Montevideo. He has also served as chairman of International Private Client Group Latin America and became a member of the Executive Committee. Additionally, he held the position of Chairman of Merrill Lynch International Banks and participated in several investment banking deals, debt offerings and privatizations. He has also held the positions of Senior Vice President and member of the GPC Executive Committee, as well as Director of Merrill Lynch Cayman Bank and Trust Company.
Dr. Frederick Oei, MD
Dr. Oei earned his medical degree at Udayana University in Bali, Indonesia in 1998. He continued his post-doctoral studies at the Stanford Medical Hospital Cardiovascular Division in interventional cardiology where he focused on medical devices. During his time at Stanford, Dr. Oei researched drug delivery stents, percutaneous transluminal laser revascularization, atherectomy, stem cell implantation, and many other related topics.
In 2000, together with a private equity group, he began investing in promising interventional cardiology start-up companies in the US. He is continues to pursue new medical ventures world wide especially in the South East Asia and China.